3D Systems announced the appointment of Mr. Bert Bruce to the company's Medical Advisory Board. Mr. Bruce will join the five other members of the advisory board who have been named since the Board's establishment in May 2022: Dr. Stephen K. Klasko, former President and CEO of Thomas Jefferson University and Jefferson Health; The Honorable David J. Shulkin, former U.S. Secretary of Veterans Affairs; The Honorable Alex Azar, former U.S. Health & Human Services Secretary; Dr. Toby Cosgrove, former President & Chief Executive officer of the Cleveland Clinic; and Dr. Bon Ku, Professor of Medicine and Design at Thomas Jefferson University and Director of the University's Health Design Lab. The Board's primary mission is to provide strategic input, guidance, and recommendations for the company's expanding efforts in regenerative medicine.

These development efforts center on the 3D printing of vascularized tissue for use in the manufacture of human organs and a host of other non-organ applications in the human body. In addition, these custom tissue constructs are targeted for use by pharmaceutical companies for the development of new drug therapies, offering the potential for shortening development cycle times and ultimately reducing or even eliminating the need for animal trials. Mr. Bruce currently leads the U.S. Rare Disease Business Unit at Pfizer Inc. Mr. Bruce is responsible for the Pfizer Rare Disease treatment portfolio in the United States, including oversight of major pharmaceutical products, as well as for the company's Rare Disease gene therapy development pipeline.

At Pfizer, Mr. Bruce has distinguished himself as a champion for patients living with rare diseases. Prior to his current position, Mr. Bruce served as Pfizer's Vice President, Global Commercial Development, Rare Disease. In this role, Mr. Bruce led work by global teams spanning the entire breadth of the drug development cycle — from investigation and screening of early stage compounds through late-stage commercial development of successful new drugs, and also directed business development efforts to acquire new medicines and grow the company's development pipeline portfolio.

Mr. Bruce possesses over 30 years of broad pharmaceutical industry experience. In addition to his 17-year career with Pfizer, Mr. Bruce's experience includes previous business leadership and strategy roles at Janssen Pharmaceutica, part of Johnson & Johnson. Mr. Bruce is also actively involved in a variety of social and educational causes.

He is the chair of the Pfizer Global Black Community, is a member of the President's Leadership Council at Thomas Jefferson University and Jefferson Health, and is a board member for Life Sciences PA, and also for Bold Hope Inc.